Zobrazeno 1 - 10
of 19
pro vyhledávání: '"B Del Rosario Garcia"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Tyrosine kinase inhibitors (TKI) are oral drugs that have demonstrated efficacy against metastatic non-small cell lung cancer (mNSCLC) with mutation of EGFR. Aim and objectives To evaluate the efficacy and safety associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f67ac3b9bbd583a0d27f87546559f77
https://doi.org/10.1136/ejhpharm-2021-eahpconf.130
https://doi.org/10.1136/ejhpharm-2021-eahpconf.130
Autor:
GJ Nazco Casariego, B Del Rosario Garcia, F Gutiérrez Nicolás, L Cantarelli, S García Gil, JA Morales Barrios
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Regorafenib (REG) and trifluridine–tipiracil (TAS-102) are used in metastatic colorectal cancer (mCRC) after failure of conventional therapy based on fluorouracil (5-FU) schemes. Aim and objectives To evaluate the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e69108a62a40c7595dc20da5fb2348ee
https://doi.org/10.1136/ejhpharm-2021-eahpconf.126
https://doi.org/10.1136/ejhpharm-2021-eahpconf.126
Autor:
GJ Nazco Casariego, JA Morales Barrios, L Cantarelli, B Del Rosario Garcia, F Gutiérrez Nicolás, S García Gil
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Cyclin dependent kinase inhibitors (CDKs) have demonstrated efficacy in the treatment of hormone receptor positive (RH+) and human epidermal growth factor receptor 2 (HER2-) metastatic breast cancer. Aim and objectives To ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23836406dd23e5f9f27cde02ec60dee7
https://doi.org/10.1136/ejhpharm-2021-eahpconf.125
https://doi.org/10.1136/ejhpharm-2021-eahpconf.125
Autor:
GJ Nazco Casariego, L Cantarelli, E Ramos Santana, B Del Rosario Garcia, MM Viña Romero, J Oramas Rodríguez, JA Morales Barrios, F Gutiérrez Nicolás
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Different studies have shown the equivalence of the dosage regimen for pembrolizumab adjusted to the patient‘s body weight (DPC: 2 mg/kg/3 week) and the fixed dose (DF: 200 mg/3 weeks), and the equivalence between nivoluma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22cb6142af90c91e1eda99311733619f
https://doi.org/10.1136/ejhpharm-2021-eahpconf.188
https://doi.org/10.1136/ejhpharm-2021-eahpconf.188
Autor:
J Garcia Cairos, L Cantarelli, S García Gil, F Gutiérrez Nicolás, J Ramos Rodríguez, J González García, C Romero Delgado, G Calzado Gómez, GA González de la Fuente, B Del Rosario Garcia, GJ Nazco Casariego
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance Therapeutic growth in the arsenal of drugs for the treatment of severe asthma (SA) with similar efficacy profiles, safety and mechanisms of action requires multidisciplinary treatment protocols to maintain the sustainability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9095ecdc9c4b906fd84393048fdc215b
https://doi.org/10.1136/ejhpharm-2020-eahpconf.31
https://doi.org/10.1136/ejhpharm-2020-eahpconf.31
Autor:
J González García, J Ramos Rodríguez, S García Gil, GJ Nazco Casariego, L Cantarelli, J Garcia Cairos, F Gutiérrez Nicolás, B Del Rosario Garcia
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance Recently, the GEMINIS I and II studies have demonstrated how lamivudine (3TC) with dolutegravir (DTG) bitherapy in naive patients is as effective as conventional triple therapy after 48 weeks of follow-up.1 Aim and objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e283df30cd30c9e3d17c2080c8a15dab
https://doi.org/10.1136/ejhpharm-2020-eahpconf.22
https://doi.org/10.1136/ejhpharm-2020-eahpconf.22
Autor:
R Benítez González, B Del Rosario Garcia, JA Morales Barrios, L Cantarelli, GJ Nazco Casariego, C Rubio Uría, F Gutiérrez Nicolás
Publikováno v:
Section 6: Education and Research.
Background and importance One of the new advances in oncology patient care will be based on continuous control of adverse reactions derived from the use of antineoplastic treatments and on the identification of early progression of the disease in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91e10c5f6b35479e96ebcd254338d3e4
https://doi.org/10.1136/ejhpharm-2020-eahpconf.452
https://doi.org/10.1136/ejhpharm-2020-eahpconf.452
Autor:
R Ramos Díaz, L Cantarelli, A Plata Bello, GJ Nazco Casariego, B Del Rosario Garcia, F Gutiérrez Nicolás, R García Marrero, GA González de la Fuente
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Enzalutamide (ENZ) and abiraterone (AA) are two drugs that have been shown to improve survival in patients diagnosed with metastatic castration resistant prostate cancer (CRPCm). There are no direct comparison studies of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88c7439af4cbdfa5dcaec448e11e6e3c
https://doi.org/10.1136/ejhpharm-2020-eahpconf.270
https://doi.org/10.1136/ejhpharm-2020-eahpconf.270
Autor:
GJ Nazco Casariego, L Cantarelli, J González García, J Ramos Rodríguez, GA González de la Fuente, B Del Rosario Garcia, F Gutiérrez Nicolás
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Analysis of data obtained in the ‘real world’ setting is acquiring great importance in the healthcare environment. It is important to know the results obtained with different treatments outside the ideal environment offe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05136272b3521e2414997816a329b4c1
https://doi.org/10.1136/ejhpharm-2020-eahpconf.221
https://doi.org/10.1136/ejhpharm-2020-eahpconf.221